δ-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: Analgesia, locomotion, and receptor internalization

Journal of Pharmacology and Experimental Therapeutics

Volumn 342, Issue 3, 2012, Pages 799-807

  Nozaki, Chihiro ^a   Le Bourdonnec, Bertrand ^b   Reiss, David ^a   Windh, Rolf T ^b   Little, Patrick J ^b   Dolle, Roland E ^b   Kieffer, Brigitte L ^a   Gavériaux Ruff, Claire ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b ADOLOR CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; ADL 5747; ADL 5859; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; FREUND ADJUVANT; N,N DIETHYL 3 HYDROXY 4 [SPIRO(CHROMENE 2.4' PIPERIDINE) 4 YL]BENZAMIDE; N,N DIETHYL 4 [5 HYDROXYSPIRO(CHROMENE 2,4' PIPERIDINE) 4 YL]BENZAMIDE; SODIUM CHANNEL NAV1.8; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIALLODYNIC EFFECT; ARTICLE; CHRONIC PAIN; CONTROLLED STUDY; DRUG MECHANISM; GENE DELETION; GENETIC ANALYSIS; IN VIVO STUDY; INFLAMMATION; KNOCKOUT MOUSE; LOCOMOTION; MOUSE; NERVE LIGATION; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCIATIC NERVE;

ANALGESIA; ANALGESICS, OPIOID; ANIMALS; BENZAMIDES; BENZOPYRANS; DISEASE MODELS, ANIMAL; GENE KNOCK-IN TECHNIQUES; HUMANS; INFLAMMATION; LOCOMOTION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NAV1.8 VOLTAGE-GATED SODIUM CHANNEL; NEURALGIA; NEURONS; PAIN MEASUREMENT; PIPERAZINES; RECEPTORS, OPIOID, DELTA; SPIRO COMPOUNDS;

EID: 84865160696     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.188987     Document Type: Article

References (40)

1. Bilsky EJ, Calderon SN, Wang T, Bernstein RN, Davis P, Hruby VJ, McNutt RW, Rothman RB, Rice KC, and Porreca F (1995) SNC 80, a selective, nonpeptidic and systemically active opioid δ agonist. J Pharmacol Exp Ther 273:359-366.
2. Brainin-Mattos J, Smith ND, Malkmus S, Rew Y, Goodman M, Taulane J, and Yaksh TL (2006) Cancer-related bone pain is attenuated by a systemically available δ-opioid receptor agonist. Pain 122:174-181.
3. Brandt MR, Furness MS, Mello NK, Rice KC, and Negus SS (2001) Antinociceptive effects of δ-opioid agonists in Rhesus monkeys: effects on chemically induced thermal hypersensitivity. J Pharmacol Exp Ther 296:939-946. (Pubitemid 32187368)
4. Brennan F, Carr DB, and Cousins M (2007) Pain management: a fundamental human right. Anesth Analg 105:205-221. (Pubitemid 46975867)
5. Cao CQ, Hong Y, Dray A, and Perkins M (2001) Spinal δ-opioid receptors mediate suppression of systemic SNC80 on excitability of the flexor reflex in normal and inflamed rat. Eur J Pharmacol 418:79-87. (Pubitemid 32378813)
6. Chaplan SR, Bach FW, Pogrel JW, Chung JM, and Yaksh TL (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53:55-63. (Pubitemid 24238751)
7. Dondio G, Ronzoni S, Farina C, Graziani D, Parini C, Petrillo P, and Giardina GA (2001) Selective δ opioid receptor agonists for inflammatory and neuropathic pain. Farmaco 56:117-119. (Pubitemid 32372595)
8. Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F, Befort K, Gavériaux-Ruff C, Dierich A, LeMeur M, et al. (2000) Mice deficient for δ- and μ-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25:195-200. (Pubitemid 30394992)
9. Foulkes T and Wood JN (2008) Pain genes. PLoS Genet 4:e1000086.
10. Fraser GL, Gaudreau GA, Clarke PB, Ménard DP, and Perkins MN (2000) Antihyperalgesic effects of δ opioid agonists in a rat model of chronic inflammation. Br J Pharmacol 129:1668-1672. (Pubitemid 30219009)
11. Galandrin S, Oligny-LongpréG, and Bouvier M (2007) The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci 28:423-430. (Pubitemid 47087968)
12. Gallantine EL and Meert TF (2005) A comparison of the antinociceptive and adverse effects of the μ-opioid agonist morphine and the δ-opioid agonist SNC80. Basic Clin Pharmacol Toxicol 97:39-51. (Pubitemid 40903094)
13. Gavériaux-Ruff C, Karchewski LA, Hever X, Matifas A, and Kieffer BL (2008) Inflammatory pain is enhanced in δ opioid receptor-knockout mice. Eur J Neurosci 27:2558-2567. (Pubitemid 351781665)
14. Gavériaux-Ruff C and Kieffer BL (2002) Opioid receptor genes inactivated in mice: the highlights. Neuropeptides 36:62-71.
15. Gavériaux-Ruff C and Kieffer BL (2011) δ-Opioid receptor analgesia: recent contributions from pharmacology and molecular approaches. Behav Pharmacol 22:405-414.
16. Gavériaux-Ruff C, Nozaki C, Nadal X, Hever XC, Weibel R, Matifas A, Reiss D, Filliol D, Nassar MA, Wood JN, et al. (2011) Genetic ablation of δ opioid receptors in nociceptive sensory neurons increases chronic pain and abolishes opioid analgesia. Pain 152:1238-1248.
17. Glajchen M (2001) Chronic pain: treatment barriers and strategies for clinical practice. J Am Board Fam Pract 14:211-218.
18. Holdridge SV and Cahill CM (2007) Spinal administration of a δ opioid receptor agonist attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Eur J Pain 11:685-693. (Pubitemid 46830764)
19. Ito S, Mori T, and Sawaguchi T (2008) Dopamine-independent psychostimulant activity of a δ-agonist. Behav Pharmacol 19:113-119.
20. Jutkiewicz EM, Kaminsky ST, Rice KC, Traynor JR, and Woods JH (2005) Differential behavioral tolerance to the δ-opioid agonist SNC80 ([(+)-4-[(αR)-α-(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl] -(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley rats. J Pharmacol Exp Ther 315:414-422. (Pubitemid 41380538)
21. Kabli N and Cahill CM (2007) Anti-allodynic effects of peripheral δ opioid receptors in neuropathic pain. Pain 127:84-93. (Pubitemid 44959432)
22. Kawaraguchi Y, Kawaguchi M, Takahashi M, Horiuchi T, Sakamoto T, and Furuya H (2004) δ-Opioid agonist SNC80 can attenuate the development of dynorphin A-induced tactile allodynia in rats. Anesthesiology 101:546-549. (Pubitemid 38988515)
23. Le Bourdonnec B, Windh RT, Ajello CW, Leister LK, Gu M, Chu GH, Tuthill PA, Barker WM, Koblish M, Wiant DD, et al. (2008) Potent, orally bioavailable δ opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5- hydroxyspiro[chromene-2,4′-piperidine]-4-yl)benzamide (ADL5859). J Med Chem 51:5893-5896.
24. Le Bourdonnec B, Windh RT, Leister LK, Zhou QJ, Ajello CW, Gu M, Chu GH, Tuthill PA, Barker WM, Koblish M, et al. (2009) Spirocyclic δ opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy- 4-(spiro[chromene-2,4́-piperidine]-4-yl) benzamide (ADL5747). J Med Chem 52:5685-5702.
25. Liu M and Wood JN (2011) The roles of sodium channels in nociception: implications for mechanisms of neuropathic pain. Pain Med 12 (Suppl 3):S93-S99.
26. Malmberg AB and Basbaum AI (1998) Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates. Pain 76:215-222. (Pubitemid 28304959)
27. McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, Lau J, Carr D, and American Pain Society (2003) Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 4:231-256. (Pubitemid 36807905)
28. Mennicken F, Zhang J, Hoffert C, Ahmad S, Beaudet A, and O'Donnell D (2003) Phylogenetic changes in the expression of δ opioid receptors in spinal cord and dorsal root ganglia. J Comp Neurol 465:349-360. (Pubitemid 37174200)
29. Nadal X, Baños JE, Kieffer BL, and Maldonado R (2006) Neuropathic pain is enhanced in δ-opioid receptor knockout mice. Eur J Neurosci 23:830-834.
30. Otis V, Sarret P, and Gendron L (2011) Spinal activation of δ opioid receptors alleviates cancer-related bone pain. Neuroscience 183:221-229.
31. Pradhan AA, Becker JA, Scherrer G, Tryoen-Toth P, Filliol D, Matifas A, Massotte D, Gavériaux-Ruff C, and Kieffer BL (2009) In vivo δ opioid receptor internalization controls behavioral effects of agonists. PLoS One 4:e5425.
32. Pradhan AA, Befort K, Nozaki C, Gavériaux-Ruff C, and Kieffer BL (2011) The δ opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol Sci 32:581-590.
33. Pradhan AA, Walwyn W, Nozaki C, Filliol D, Erbs E, Matifas A, Evans C, and Kieffer BL (2010) Ligand-directed trafficking of the δ-opioid receptor in vivo: two paths toward analgesic tolerance. J Neurosci 30:16459-16468.
34. Qiu Y, Loh HH, and Law PY (2007) Phosphorylation of the δ-opioid receptor regulates its β-arrestins selectivity and subsequent receptor internalization and adenylyl cyclase desensitization. J Biol Chem 282:22315-22323. (Pubitemid 47267362)
35. Saitoh A, Yamada M, Yamada M, Takahashi K, Yamaguchi K, Murasawa H, Nakatani A, Tatsumi Y, Hirose N, and Kamei J (2008) Antidepressant-like effects of the δ-opioid receptor agonist SNC80 ([(+)-4-[(αR)-α-(2S,5R) -2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N, N-diethylbenzamide) in an olfactory bulbectomized rat model. Brain Res 1208:160-169.
36. Scherrer G, Imamachi N, Cao YQ, Contet C, Mennicken F, O'Donnell D, Kieffer BL, and Basbaum AI (2009) Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell 137:1148-1159.
37. Scherrer G, Tryoen-Tóth P, Filliol D, Matifas A, Laustriat D, Cao YQ, Basbaum AI, Dierich A, Vonesh JL, Gavériaux-Ruff C, et al. (2006) Knockin mice expressing fluorescent δ-opioid receptors uncover G protein-coupled receptor dynamics in vivo. Proc Natl Acad Sci U S A 103:9691-9696. (Pubitemid 43955886)
38. Stirling LC, Forlani G, Baker MD, Wood JN, Matthews EA, Dickenson AH, and Nassar MA (2005) Nociceptor-specific gene deletion using heterozygous NaV1.8-Cre recombinase mice. Pain 113:27-36. (Pubitemid 40038443)
39. Urs NM, Daigle TL, and Caron MG (2011) A dopamine D1 receptor-dependent β-arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice. Neuropsychopharmacology 36:551-558.
40. Zheng H, Loh HH, and Law PY (2010) Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications. IUBMB Life 62:112-119.